2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. IL-6 Isoform
  6. IL-6 Inhibitor

IL-6 Inhibitor

IL-6 Inhibitors (82):

Cat. No. Product Name Effect Purity
  • HY-P99012
    Clazakizumab
    		Inhibitor
    Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection.
  • HY-B0667S1
    Balsalazide-d4
    		Inhibitor
    Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
  • HY-161833
    HSP90-IN-31
    		Inhibitor
    HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056). Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen.
  • HY-146547
    Anti-inflammatory agent 17
    		Inhibitor
    Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI).
  • HY-18325A
    AN-3485 hydrochloride
    		Inhibitor
    AN-3485 hydrochloride is a benzoxaborole analogue and an orally active antagonist of the Toll-like pathway. AN-3485 hydrochloride can inhibit TLR-mediated inflammatory cytokine secretion and has significant anti-inflammatory activity. In addition, AN-3485 hydrochloride also has certain anti-tumor activity.
  • HY-115910
    Y13g
    		Inhibitor
    Y13g is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals.
  • HY-153330
    TNF-α-IN-10
    		Inhibitor
    TNF-α-IN-10 (compound 8a) is a IL-6 and TNF-α inhibitor. TNF-α-IN-10 shows anti-inflammatory activity.
  • HY-15509
    Semapimod
    		Inhibitor
    Semapimod, an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod has potential in a variety of inflammatory and autoimmune disorders.
  • HY-N0604R
    Ginsenoside Rh1 (Standard)
    		Inhibitor
    Ginsenoside Rh1 (Standard) is the analytical standard of Ginsenoside Rh1. This product is intended for research and analytical applications. Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
  • HY-162681
    eeAChE-IN-3
    		Inhibitor
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research.
  • HY-P10710
    BMP-4
    		Inhibitor
    BMP-4 is a penetrating heparin-binding peptide with anti-inflammatory and anti-chondrogenic functions. In murine chondrocytes and macrophages, BMP-4 regulates the iNOS-IFN-IL6 signaling pathway to inhibit the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 in a dose-dependent manner, effectively suppressing inflammation and alleviating various arthritis symptoms.
  • HY-157992
    LM-021
    		Inhibitor
    LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research.
  • HY-149087
    MR2938
    		Inhibitor
    MR2938 is a potent AChE inhibitor, with an IC50 of 5.04 μM. MR2938 also suppresses NO production obviously (IC50 = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.
  • HY-173180
    5-LOX-IN-8
    		Inhibitor
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD).
  • HY-170415
    EGR-1-IN-3
    		Inhibitor
    EGR-1 IN-3 (Compound 36) is an early growth response 1 (EGR-1)-DNA binding disruptor. EGR-1-IN-3 inhibits TNFα-induced binding of EGR-1 to DNA and expression of genes associated with inflammation (such as TSLP, IL-31, IL-6 and CCL2). EGR-1-IN-3 can be used in the study of inflammatory diseases.
  • HY-111326
    Naphazoline
    		Inhibitor 99.74%
    Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.
  • HY-149496
    Akt/NF-κB/MAPK-IN-1
    		Inhibitor
    Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways.
  • HY-168922
    Keap1-Nrf2-IN-25
    		Inhibitor
    Keap1-Nrf2-IN-25 (Compound 19) is a potent Keap1-Nrf2 inhibitor (IC50 of 0.55 μM) with Keap1 binding affinity (Kd of 0.50 μM). Keap1-Nrf2-IN-25 activates Nrf2, reduces ROS and pro-inflammatory cytokines (IL-1β, IL-6). Keap1-Nrf2-IN-25 exerts protective effects against DSS (HY-116282)-induced colitis.
  • HY-155027
    DPP-4-IN-8
    		Inhibitor
    DPP-4-IN-8 (compound 27) is a potent and selective DPP4 (dipeptidyl peptidase 4) inhibitor, with a Ki of 0.96 μM. DPP-4-IN-8 blocks the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells. DPP-4-IN-8 also dose-dependently suppresses the expression levels of the chemokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β).
  • HY-169420
    IL-6-IN-1
    		Inhibitor
    IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC50 of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model.